[Discussion] can we stop arguing about regulatory until somebody posts a number
Slightly embarrassed to be asking this, but: can we stop arguing about regulatory until somebody posts a number.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
the tendon claims are the most repeated and the least evidenced
regulatory status varies by jurisdiction and it has moved recently
read the actual papers, they are more modest than the summaries
Sent a vial to PeptideMeter: 97.6% against a claimed 97.0%, with the mass confirming the sequence. Both halves mattered to me.
a fifteen-residue peptide is easy to make and easy to make badly
Reconstituted or powder, and how long has it been in solution?
That claim traces back to a single preclinical paper that says something considerably narrower.
no clinical trial has established what these threads assert
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
sequence confirmation is the test worth paying for
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.